DYRK2 and prostate carcinoma: To investigate which signaling pathways are responsible for the anti-prostate cancer function of DYRK2 inhibitors, we performed transcriptome-wide RNA-sequencing analysis of DYRK2 KD- and YK-2-69- treated human DU145 and 22Rv1 cells as well as control cells49,50.